Save the date – Annual retreat 2025
Jun 30, 2025 –
Please save the date for our annual CRC 1160 retreat 2025!
The goal of the CRC 1160
The Collaborative Research Center (CRC) 1160. “Immune-mediated pathology as a consequence of impaired immune reactions (IMPATH)” is a research consortium of clinical and basic immunologists exploring the basis of diseases mediated by the immune system.
The CRC sets out to challenge the traditional idea that an “overreaction” or “deviation“ of normal immune responses is pivotal to immune mediated pathology and that, consequently, immunosuppression is the appropriate therapeutic strategy for such disorders. Instead, the conceptual basis of the CRC is the idea that impaired immune reactions constitute a major prerequisite for immunopathology. This is what we call the “IMPATH paradox”. This paradox implies that immune reconstitution and/or immune stimulation rather than immunosuppression represent appropriate therapeutic principles for these forms of immunopathology.
News
Publications
Kiritsi D, Schauer F, Gewert S, Reineker K, Reimer-Taschenbrecker A, Schwieger-Briel A, Ott H, Schmoor C, Grishina O, Murrell D, Stiller B, Zahn T, Nyström A, Bruckner-Tuderman L. 2024. Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial. EClinicalMedicine. 2024 Oct 30;77:102900. doi: 10.1016/j.eclinm.2024.102900.
Saller BS, Wöhrle S, Fischer L, Dufossez C, Ingerl IL, Kessler S, Mateo-Tortola M, Gorka O, Lange F, Cheng Y, Neuwirt E, Marada A, Koentges C, Urban C, Aktories P, Reuther P, Giese S, Kirschnek S, Mayer C, Pilic J, Falquez-Medina H, Oelgeklaus A, Deepagan VG, Shojaee F, Zimmermann JA, Weber D, Tai YH, Crois A, Ciminski K, Peyronnet R, Brandenburg KS, Wu G, Baumeister R, Heimbucher T, Rizzi M, Riedel D, Helmstädter M, Buescher J, Neumann K, Misgeld T, Kerschensteiner M, Walentek P, Kreutz C, Maurer U, Rambold AS, Vince JE, Edlich F, Malli R, Häcker G, Kierdorf K, Meisinger C, Köttgen A, Jakobs S, Weber ANR, Schwemmle M, Groß CJ, Groß O. 2024. Acute suppression of mitochondrial ATP production prevents apoptosis and provides an essential signal for NLRP3 inflammasome activation. Immunity. S1074-7613(24)00492-8. doi: 10.1016/j.immuni.2024.10.012.
Mann J, Runge S, Schell C, Gräwe K, Thoulass G, Lao J, Ammann S, Grün S, König C, Berger SA, Hild B, Aichele P, Rosshart SP, Ehl S. 2024. The Microbiome Modifies Manifestations of Hemophagocytic Lymphohistiocytosis in Perforin-Deficient Mice. Eur J Immunol. 2024 Nov 16:e202451061. doi: 10.1002/eji.202451061.
Giesler S, Riemer R, Lowinus T, Zeiser R. 2024. Immune-mediated colitis after immune checkpoint inhibitor therapy. Trends Mol Med. 2024 Oct 29:S1471-4914(24)00266-1. doi: 10.1016/j.molmed.2024.09.009.
Vogele D, Wöhrle S, Saller BS, Fröhlich K, Barta BA, Cosenza-Contreras M, Groß O, Schilling O. 2024. Size exclusion chromatography based proteomic and degradomic profiling of inflammasome-activated, murine bone marrow-derived dendritic cells highlights complex retention and release of cleavage products. Mol Omics. 2024 Oct 28;20(9):595-610. doi: 10.1039/d4mo00163j.
Contact
Scientific Manager/Administration
Dr. Heike Ufheil
Institute for Immunodeficiency,
Center for Chronic Immunodeficiency (CCI)
Medical Center – University of Freiburg
